Dr. Schuster discusses how radiotracers will be used to treat prostate cancer in the future
“I think that we keep getting better and better tools…[and] I think understanding how to utilize these tools will be a challenge in the future,” says David M. Schuster, MD, FACR.
In this video, David M. Schuster, MD, FACR, discusses the takeaways and further research associated with the study, “Detection rates of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT),” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Schuster is a professor of urology and radiology and imaging sciences, a GRA distinguished cancer scientist, and the director of the division of nuclear medicine and molecular imaging at the Emory University School of Medicine in Atlanta, Georgia.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
![Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Furologytimes%2F05175eccc72521b2df7a5a848d1602a44b55382e-640x640.webp%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "Study compares 18F-based PSMA radiotracers to [68Ga]Ga-PSMA-11")
Bone scans overstage prostate cancer vs PSMA-PET in initial setting
November 21st 2023"Rather than receiving definitive radiation treatment for localized disease, these patients may have received treatment aimed at preventing the further spread of what was incorrectly identified as metastatic disease," says Thomas Hope, MD.
